EP1119373A1 - Oxybutyin enthaltende formulierungen und verfahren zu ihrer verwendung - Google Patents
Oxybutyin enthaltende formulierungen und verfahren zu ihrer verwendungInfo
- Publication number
- EP1119373A1 EP1119373A1 EP99951751A EP99951751A EP1119373A1 EP 1119373 A1 EP1119373 A1 EP 1119373A1 EP 99951751 A EP99951751 A EP 99951751A EP 99951751 A EP99951751 A EP 99951751A EP 1119373 A1 EP1119373 A1 EP 1119373A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- bladder
- concentration
- oxybutynin chloride
- infuser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 238000009472 formulation Methods 0.000 title abstract description 16
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 title description 10
- 229960005434 oxybutynin Drugs 0.000 title description 9
- 238000000034 method Methods 0.000 title description 5
- ZKNJEOBYOLUGKJ-ALCCZGGFSA-N (z)-2-propylpent-2-enoic acid Chemical compound CCC\C(C(O)=O)=C\CC ZKNJEOBYOLUGKJ-ALCCZGGFSA-N 0.000 claims abstract description 96
- 229960002016 oxybutynin chloride Drugs 0.000 claims abstract description 96
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000006184 cosolvent Substances 0.000 claims description 11
- 239000006172 buffering agent Substances 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
- 208000029162 bladder disease Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims description 6
- 206010046494 urge incontinence Diseases 0.000 claims description 6
- 208000026533 urinary bladder disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000004064 dysfunction Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims description 4
- 206010029279 Neurogenic bladder Diseases 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000872 buffer Substances 0.000 abstract description 9
- 230000036760 body temperature Effects 0.000 abstract description 6
- 206010069632 Bladder dysfunction Diseases 0.000 abstract description 4
- 230000003139 buffering effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 37
- 239000000047 product Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004809 Teflon Substances 0.000 description 3
- 229920006362 Teflon® Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 2
- MZOUVOQNHXITAB-UHFFFAOYSA-N 4-chlorobuta-1,3-diyn-1-ol Chemical compound OC#CC#CCl MZOUVOQNHXITAB-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Definitions
- the present invention relates to oxybutynin formulations which are stable at body temperature and their use in treating bladder dysfunction. These formulations are suitable for extended diffusion into the bladder using infuser devices.
- oxybutynin chloride benzeneacetic acid, ⁇ -cyclohexyl- ⁇ -hydroxy-, 4-(diethylamino)-2-butynyl ester hydrochoride, ( ⁇ )
- Oxybutynin chloride (OC) is available in syrup and tablet form (United States Pharmacopoeia Ufficial Monographs 23:1127-1129).
- OC Oxybutynin chloride
- OC has been administered directly to the bladder via a catheter (intravesical administration).
- Brendler et al. J. Urology 141:1350-1352, 1989
- the solution was retained for 30 minutes.
- Madersbacher et al. Paraplegia 29:84-90, 1991
- Greenfield et al. J. Urology 146:532-534, 1991
- OC solutions described above are suitable for temporary instillation into the bladder, they are not sufficiently stable for extended delivery into the bladder over several weeks or months.
- the present invention provides stable OC compositions for use in intravesical infuser devices for extended diffusion into the bladder.
- One embodiment of the present invention is a pharmaceutical composition comprising oxybutynin chloride, wherein the composition is stable at 37°C for at least 12 hours when placed within the bladder.
- the oxybutynin chloride has a concentration of between about 1 mg/ml and 30 mg/ml. More preferably, the concentration of oxybutynin chloride is between about 10 mg/ml and 25 mg/ml. Most preferably, the concentration of oxybutynin chloride is about 20 mg/ml.
- the composition has a pH of between about 3.0 and 5.0; preferably between about 3.5 and 4.5; more preferably about 4.0.
- the composition may further comprise a buffering agent having a concentration of between about 0.005 M and 0.1 M.
- the buffering agent has a concentration of between about 0.01 and 0.05 M.
- the buffering agent is acetate or citrate.
- the composition may further comprise a cosolvent.
- the cosolvent is a viscosity-enhancing agent.
- the viscosity-enhancing agent is a carbohydrate or cellulosic viscosity enhancing agent, such as carboxymethylcellulose or hydroxypropylmethylcellulose.
- the composition may be provided in combination with an infuser capable of releasing the composition at a particular flow rate.
- the infuser is an intravesical infuser.
- the flow rate is less than about 400 ⁇ l/hour.
- the present invention also provides the use of a composition comprising oxybutynin chloride, wherein the composition is stable at 37°C for at least 12 hours when placed within the bladder, in the preparation of a medicament for treatment of a bladder disorder.
- the bladder disorder is secondary urge incontinence, hyperreflexive voiding dysfunction, neurogenic bladder or decreased bladder capacity.
- the oxybutynin chloride is delivered to the bladder at a rate not exceeding about 400 ⁇ l/hour.
- the present invention provides stable, autoclavable OC pharmaceutical compositions for use in an infuser.
- the infuser pump may be placed outside the body and attached to a catheter for instillation of the composition into the bladder.
- the composition is placed in an intravesical infuser.
- These compositions are stable to increased temperature (up to at least 50°C for at least 3 weeks), autoclaving, and to contact with parts of an intravesical infuser.
- One preferred intravesical infuser is described in published PCT Application No. W099/24106.
- the excellent temperature and contact stability of the present OC compositions allows extended delivery into the bladder for days, weeks or months, compared to previous OC compositions which do not exhibit such stability and are typically retained within the bladder for several hours.
- the increased stability is due to several factors, including concentration of OC, phi and buffer concentration.
- the OC compositions of the invention are well suited for use in the bladder due to their increased stability at both ambient and body temperature (Example 1).
- the OC compositions of the invention are stable at body temperature for at least 12, 24 or 48 hours. In a more preferred embodiment, the compositions are stable at body temperature for at least 3-7 days. In a most preferred embodiment, the compositions are stable at body temperature for about 7, 14, 21 or 28 days.
- stabilize indicates that preferably no more than 5%, more preferably no more than 3%, and most preferably no more than 1 % of the OC in the composition is degraded while present in the bladder.
- the OC composition is an aqueous solution.
- the concentration of OC in solution is between about 0.1 mg/ml, 0.3 mg/ml, 0.5 mg/ml, 0.8 mg/ml, 1 mg/ml, 5 mg/ml or 10 mg/ml, and 30 mg/ml. In a more preferred embodiment, the concentration is between about 10 mg/ml and about 25 mg/ml. In a most preferred embodiment, the concentration is about 20 mg/ml. If the concentration is too low, one cannot deliver the desired dosage of OC over an extended time with a reasonably-sized device. If the concentration of OC is too high, it will be insoluble and will precipitate out of solution.
- the pH of the OC composition is between about 3.0 and about 5.0; preferably between about 3.5 and 4.5; more preferably, about 4.0.
- OC is provided in a buffer capable of providing adequate buffering capacity at a pH between about 3.0 and 5.0.
- Suitable buffers include citrate and acetate.
- the buffer concentration is typically between about 0.005 M and 0.1 M, preferably between 0.01 M and 0.05 M, more preferably about 0.01 M.
- the OC compositions of the invention may further include a cosolvent.
- suitable cosolvents include glycol cosolvents such as glycerol and propylene glycol, which also serve as viscosity-enhancing (thickening) agents.
- the cosolvent is a carbohydrate or cellulosic viscosity-enhancing agent such as carboxymethylcellulose, hydroxypropylmethylcellulose, or any other viscosity-enhancing agent well known in the art, to help control the flow rate of the OC from the infuser.
- the viscosity-enhancing agent is a non-sugar. Complex carbohydrates are considered to be non-sugars, whereas mono- and disaccharides are considered to be sugars.
- the viscosity of the composition is between about 10 cps and 100 cps (centipoise), corresponding to between about 0.5% and 2.0% thickening agent. More preferably, the viscosity is between about 25 cps and 75 cps. Most preferably, the viscosity is between about 40 cps and 60 cps. In another preferred embodiment, the flow rate of the composition from the infuser is within the range of 0.1, 1, 5, 10, 25, 50, 75, 100, 150 or 200, 300 or 400 ⁇ l/hour.
- compositions of the invention are formulated with pharmaceutically acceptable carriers such as water, Ringer's solution and isotonic sodium chloride solution using methods well known in the art.
- the compositions may further include one or more of a demulcent, stabilizer, preservative, coloring agent, or any other additive conventional in the art.
- a demulcent, stabilizer, preservative, coloring agent, or any other additive conventional in the art For assistance in formulating the compositions of the present invention, one may refer to Remington's Pharmaceutical Sciences, 15th Edition, Mack Publishing Co., Easton, PA.
- Syrups are pharmaceutical formulations or solutions for oral administration which are sweet and viscid, typically containing one or more sugars in sweetening agents such as sucrose, sorbitol or glycerol in an amount from about 1 % to near saturation.
- the OC composition of the invention is not a syrup and contains essentially no sweetening agents. If present, the concentration of these sugars or sweetening agents is significantly less than the concentration of OC or of buffer salts (e.g., 0.01 %-0.1 %).
- the OC compositions of the invention are used to treat bladder dysfunction including secondary urge incontinence, hyperreflexive voiding dysfunction, neurogenic bladder and decreased bladder capacity.
- an intravesical infuser is inserted into the bladder via the urethra, and the OC compositions are placed in the intravesical infuser.
- the OC continuously diffuses out of the infuser over the course of several weeks or months to provide a maximum therapeutic benefit. This is possible because of the high concentration and the stability of the OC compositions of the invention.
- Formulation studies were conducted to develop a stable formulation of oxybutynin chloride solution for use in dosing and toxicity studies.
- the initial stability study was performed on various formulations of OC solutions (Reference No. RD 186072).
- Initial formulations containing 20 mg/ml OC were compounded at pH 3.0, 4.0 and 5.0.
- a formulation containing citrate buffer was also tested. These formulations are shown in Table 1.
- OC solution formulations (RD186072-1, RD186072-2 and RD186072-3) were compounded and placed in 10 ml clear glass vials sealed with a Teflon faced stopper. The filled units were incubated at 40°C and
- HPLC high performance liquid chromatography
- the mobile phase consisted of 600 ml aceotonitrile and 400 ml of buffer, pH 7.0.
- the HPLC system was prepared with the following parameters: wavelength, 220 nm; injection volume, 10 ⁇ l; column temperature, 40°C; flow rate, 2 ml/min.
- the working standard solution was prepared by accurately weighing approximately 30 mg oxybutynin reference standard, transferring to a 25 ml volumetric flask and diluting to volume with acetonitrile.
- the working standard was injected and the mobile phase adjusted if necessary to meet the following suitability requirements for the oxybutynin peak: theoretical plates, > 3,000; tailing factor, ⁇ 2.0.
- Five replicate injections of the working standard were performed and the oxybutynin peak responses as area were recorded.
- the relative standard deviation (RSD) of the replicate areas was ⁇ 2.0%.
- Duplicate injections of the assay preparations were performed and the oxybutynin peak responses as area were recorded.
- the concentration of OC in the sample was calculated as described above.
- a s ⁇ mean oxybutynin peak area in the assay preparation
- Table 2 show that there is no significant degradation in OC over three weeks at 40°C to 50°C.
- %LC indicates the percentage of OC present as determined by HPLC.
- OC solutions Three formulations of OC solutions (RD186072-1, RD186072-2 and RD186072-3) were compounded and placed in 10 ml clear glass vials sealed with a TEFLON faced stopper. The filled units were autoclaved at 121 °C for 30 minutes. The autoclaved units were incubated at 40°C for one week and assayed for OC. The results for zero time and one week autoclaved samples are shown in Table 3. The results indicate that the product can be autoclaved and that the product can then be stored without significant degradation of OC for 3 weeks at 40°C.
- Device contact study A contact study was performed using various parts of an intravesical infuser which would come into contact with the OC solution during its use to determine whether any of the device contact parts would adversely affect the product.
- the contact study (RD186077) was performed to determine the effect of any contact between the product and the device materials and surfaces that may occur during usage of the product in the device.
- OC Solution RD-186072-2 (Table 1) was compounded and placed in 10 ml clear glass vials sealed with a TEFLON spaced stopper. Prior to sealing the vials, the delivery device was taken apart and each contact part was placed in contact with 10 ml of the OC solution. The vials containing the contact parts and OC solution were stored at room temperature for one week. The solution was assayed at one week to determine if there was any decrease in the amount of OC in solution. The results (Table 4) indicate no significant change in the amount of OC when in contact with the device for one day at room temperature. Table 4
- the different solutions that were compounded for the dog dose escalation study (Example 5) when added to dog urine, contained precipitated OC after the addition of a small ( ⁇ 1 ml) amount of solution to 25 ml dog urine, with the exception of the 2 mg/ml OC solution which did not show any precipitation even after the addition of 10 ml to 25 ml of dog urine.
- a 10 mg/ml OC solution was also added to 25 ml of dog urine and precipitation was observed after the addition of 1 ml of the solution.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US231139 | 1988-08-11 | ||
US10322898P | 1998-10-05 | 1998-10-05 | |
US103228P | 1998-10-05 | ||
US09/231,139 US6087396A (en) | 1998-10-05 | 1999-01-15 | Oxybutynin formulations and method of use |
PCT/US1999/023024 WO2000020035A1 (en) | 1998-10-05 | 1999-10-01 | Oxybutynin formulations and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1119373A1 true EP1119373A1 (de) | 2001-08-01 |
Family
ID=26800209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99951751A Withdrawn EP1119373A1 (de) | 1998-10-05 | 1999-10-01 | Oxybutyin enthaltende formulierungen und verfahren zu ihrer verwendung |
Country Status (6)
Country | Link |
---|---|
US (1) | US6087396A (de) |
EP (1) | EP1119373A1 (de) |
JP (1) | JP2002526423A (de) |
AU (1) | AU6412599A (de) |
CA (1) | CA2346332A1 (de) |
WO (1) | WO2000020035A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013127834A1 (en) | 2012-02-28 | 2013-09-06 | Ge Healthcare As | Vial with free float valve for sterile pharmaceutical |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6436428B1 (en) | 2000-03-21 | 2002-08-20 | Enhance Pharmaceuticals, Inc. | Device and method for treating urinary incontinence in females |
US6545046B2 (en) * | 2000-08-30 | 2003-04-08 | Theramax Inc. | Method for enhanced delivery of oxybutynin and compositions thereof |
US8563592B2 (en) | 2001-11-01 | 2013-10-22 | Spectrum Pharmaceuticals, Inc. | Bladder cancer treatment and methods |
WO2003037314A2 (en) * | 2001-11-01 | 2003-05-08 | Spectrum Pharmaceuticals, Inc. | Medical compositions for intravesical treatment of bladder cancer |
US6949125B2 (en) | 2002-04-16 | 2005-09-27 | Boston Scientific Scimed, Inc. | Ureteral stent with end-effector and related methods |
US20070172508A1 (en) * | 2006-01-26 | 2007-07-26 | Paul Zupkas | Transluminal drug delivery methods and devices |
DE102007003765A1 (de) * | 2007-01-19 | 2008-07-24 | Farco-Pharma Gmbh | Pharmazeutische Zusammensetzung zur Behandlung von Inkontinenz |
NL2023160B1 (en) * | 2018-05-17 | 2020-05-20 | Notoxins Ip B V | Aqueous formulations comprising oxybutynin for topical treatment of skin diseases |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4519801A (en) * | 1982-07-12 | 1985-05-28 | Alza Corporation | Osmotic device with wall comprising cellulose ether and permeability enhancer |
US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US5082668A (en) * | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
US5399359A (en) * | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
US5674895A (en) * | 1995-05-22 | 1997-10-07 | Alza Corporation | Dosage form comprising oxybutynin |
US6171298B1 (en) * | 1996-05-03 | 2001-01-09 | Situs Corporation | Intravesical infuser |
-
1999
- 1999-01-15 US US09/231,139 patent/US6087396A/en not_active Expired - Fee Related
- 1999-10-01 CA CA002346332A patent/CA2346332A1/en not_active Abandoned
- 1999-10-01 WO PCT/US1999/023024 patent/WO2000020035A1/en not_active Application Discontinuation
- 1999-10-01 AU AU64125/99A patent/AU6412599A/en not_active Abandoned
- 1999-10-01 EP EP99951751A patent/EP1119373A1/de not_active Withdrawn
- 1999-10-01 JP JP2000573393A patent/JP2002526423A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO0020035A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013127834A1 (en) | 2012-02-28 | 2013-09-06 | Ge Healthcare As | Vial with free float valve for sterile pharmaceutical |
Also Published As
Publication number | Publication date |
---|---|
US6087396A (en) | 2000-07-11 |
JP2002526423A (ja) | 2002-08-20 |
WO2000020035A1 (en) | 2000-04-13 |
AU6412599A (en) | 2000-04-26 |
CA2346332A1 (en) | 2000-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10238640B2 (en) | Pharmaceutical suspension composition | |
CN102176920B (zh) | 姜黄素及其用于治疗眼科疾病的方法 | |
KR100341497B1 (ko) | 로테프레드놀에타보네이트의현탁액 | |
TWI324925B (en) | Ophthalmic composition | |
US20170216321A1 (en) | Liquid formulations of compounds active at sulfonylurea receptors | |
US4942167A (en) | Pharmaceutical compositions of piroxicam in aqueous solutions and process for their preparation | |
SK285650B6 (sk) | Vodné prípravky moxifloxacínu a chloridu sodného,spôsob ich výroby a kombinovaný preparát | |
KR102656841B1 (ko) | 레파뮬린의 주사가능한 약제학적 제형 | |
EP1073467A2 (de) | Zusammensetzungen enthaltend glykolderivate und alkohole | |
US5998430A (en) | Use of trospium chloride and 2-component system for the same | |
US6087396A (en) | Oxybutynin formulations and method of use | |
US8809393B2 (en) | Injectable preparations of diclofenac and its pharmaceutically acceptable salts | |
EP3010485A1 (de) | Stabile bromfenac-lösung | |
US9211251B2 (en) | Injectable preparations of diclofenac and its pharmaceutically acceptable salts | |
JPH1029937A (ja) | メフェナム酸水溶液製剤 | |
US20140107130A1 (en) | Oral Solution Formulations of Aripiprazole | |
AU2018318123A1 (en) | Aqueous nebulization composition | |
WO2022268190A1 (zh) | 一种酮咯酸液体组合物、其制备方法及应用 | |
CN114259556B (zh) | 人干扰素α2b喷雾剂及其制备方法 | |
EP4282402A1 (de) | Ophthalmische zubereitung zur behandlung von makulaödemen, optischer neuritis und nichtinfektiöser endophthalmitis durch verabreichung von augentropfen | |
CN116847826A (zh) | 包含左氧氟沙星和酮咯酸的眼用组合物、其制备方法和用途 | |
MXPA94003569A (en) | Stable quinolone and naphthyridine premix formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010501 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20020311 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020924 |